Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (October 2022)
15 slides from Enveric Biosciences's investor presentation, Oct 24, 2022
Slide 1: Corporate Presentation Q4 2022
EY Slee ccn~ Mental Health™ BIOSCIENCES CORPORATE PRESENTATION Q4 2022
Slide 2: Disclaimer
Disclaimer No Offer oF Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Enveric Biosciences is a biotechnology company
Enveric Biosciences is a biotechnology company dedicated to the development of novel small- molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Our mission is to pioneer new and innovative solutions with the potential to have profound effects on patients and their
Slide 4: Executive Summary
Executive Summary Enveric Biosciences (NASDAQ: ENVB) + Comprised of a team of experienced CNS drug developers who have successfully led programs from inception to market approval + Drug platform that has created 500+ New Chemical Entities to date, intended to deliver greater benefits to patient as c
Slide 5: Management Team
Dr. Kevin Leach D Dr. Peter Facchini Dr. Rick Light i . Joseph Tucker Mr. Avani Kanubaddi Dr. Bob Dagher Mr. Rob Dickey Teopeaaes Chief hates President & Chief Chief Medical Officer Interim Chief Innovation Officer Vice-President, CMC Translational & Non- Officer & Director Operating Officer Chief F
Slide 6: Anxiety Continues to be a Tremendous Unmet Need with Limited Innovation in Nearly Two Decades
Anxiety Continues to be a Tremendous Unmet Need with Limited Innovation in Nearly Two Decades + Anxiety disorders are among the most common CNS Disorders, ranking second. + Anxiety disorders are chronic conditions that remain poorly controlled despite available treatments. + The last FDA-approved dr
Slide 7: Limitations of Current Anxiety Pharmacologic Treatments
Limitations of Current Anxiety Pharmacologic Treatments Anxiolytics: 1st Generation Psilocybin: * Benzodiazepines (BZD) * Currently under investigation * Selective serotonin reuptake inhibitors (SSRIs) * Challenges with patentability * Serotonin norepinephrine reuptake inhibitors (SNRIs) + Anecdotal
Slide 8: EVM201 Series - Enhanced Drug-Like Properties
EVM201 Series - Enhanced Drug-Like Properties EVM201: next generation synthetic psilocybin analogues Rationally designed prodrugs of the active metabolite: psilocin Altered metabolic and pharmacokinetic properties to achieve improved Risk/Benefit profile * Optimized delivery route © Canbe administer
Slide 9: EVM201 Molecules release psilocin and Produce Modulated Response in Animal Model of Hallucination
EVM20! Molecules release psilocin and Produce Modulated Response in Animal Model of Hallucination EVM201 molecules, at different dose levels and brain exposures, produce consistent level of 5-HT2A-mediated Head Twitch Response in mice 3 8 P20 H Range of Psilocybin-induced HTR — 3 8 5 + = 10 € 2 sf o
Slide 10: oo] oo]
= = oo] oo] @ Q 5 5 a a a a 2 2 2 2 & & = = Control Stress Control Stress Stress Control Stress Control Stress Stress VEH PSIL EVM201 VEH PsIL (EVM201 + PSIL: Psilocybin + Data on File; Enveric Biosciences 10
Slide 11: EVM301 Series
EVM301 Series GEN-3’s Holistic Approach for Treating Mental Health Diseases New Chemical Entities + Small molecules with novel properties targeting specific brain receptors and networks to generate new clinical benefit + Removes the need for close intervention of a health care professional during th
Slide 12: EVM Program Pipeline
EVM Program Pipeline Two Separate Series of Differentiated Assets for Mental Health Indications UPCOMING. ASSET GROUP INDICATION DISCOVERY PRECLINICAL CLINICAL MILESTONE TIMELINE EVM201 . Anxiety Disorder @ . a series IND Filing Q4 2023 EVM301 Undisclosed @ + Lead Selection Q4 2023 series 12
Slide 13: Enveric Intellectual Property
Enveric Intellectual Property Three Moats Protecting Enveric’s Strong Intellectual Property Inner Moat Second Moat Outer Moat + 5 years New + Submitted 15+ patent + IP Discovery Chemical Entity applications covering Platform (NCE) and 3 years EVM201 & EVM301. New Clinical Study * Psybrary™ and (NCS)
Slide 14: Jal
Jal nasdaq :ENVB Enveric Biosciences is a biotechnology company dedicated to the development of novel small- molecule therapeutics for the treatment of anxiety, depression and addiction disorders. Cash and Cash equivalents + $18 million as of June 2022. Experienced Team + Team of experienced CNS dru
Slide 15: Thank you!
EY Slee ccn~ Mental Health™ BIOSCIENCES Thank you!
Enveric Biosciences — Investor Presentation (October 2022) on 6ix